Be part of an international effort to conquer Waldenström’s macroglobulinemia (WM)
Be part of the next WM breakthrough and ensure people living with WM all around the world are given the best possible chance at conquering this disease.
Help ensure people living with rare blood cancers aren’t left behind
Waldenström’s macroglobulinemia (WM) is a rare and incurable form of blood cancer that typically affects older adults. WM normally develops over a long period of time and can significantly impact a person’s quality of life once diagnosed.
WM receives lower levels of research funding than many other forms of blood cancer and there are fewer opportunities for patients to access clinical trials. Therefore investment in research is desperately needed to understand the drivers of WM, and to develop more targeted and effective therapies for people living with WM. The international WM community is coming together to co-fund new and exciting research through the IWMF-LLS Strategic Research Roadmap Initiative.
IWMF-LLS Strategic Research Roadmap Initiative
The International Waldenström’s Macroglobulinemia Foundation (IWMF) and The Leukaemia and Lymphoma Society (LLS) recently announced the third IWMF-LLS Strategic Research Roadmap Initiative to help further knowledge in four key domains of WM research:
- Genomics and epigenomics
- Bone marrow/tumour microenvironment
The IWMF supports research to better understand the biology of WM, with the goals of improving quality of life for WM patients, discovering new treatments, and ultimately, finding a cure. Read more about the IWMF's research strategy here.
Under the Roadmap Initiative, the IWMF awards Roadmap grants for 2-4 new research proposals each year, depending on funding availability.
All proposals are reviewed by an independent committee composed of selected members of the IWMF Scientific Advisory Committee and other experts in the field.
Life’s good for Michael thanks to “a pill for life”
Michael van Ewijk “hasn’t looked back” since starting a new treatment on an international trial almost five years ago.
It involves taking three tablets first thing each morning. He was the first Australian to have this new treatment as a monotherapy and it’s been lifesaving.
“My life is normal now,” said Michael, 69, of Milton in regional NSW, who was diagnosed with Waldenström’s macroglobulinaemia (WM) in May 2005.
“I’m still on the trial and it still works!”
A big thank you to our Supporters
The real heroes who are kindly helping us achieve our goal
F And S Grinlinton
Jenny Davis Oam
James Houston Carruthers
Endre & Vicky.